Revenue
2024
2025
2026
Psyence Biomedical Ltd. (PBM)
Price$4.54Cached quote
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | — | — |
| Research & development | $1.5M | $342,168 | $954,593 | $1.6M | — |
| Operating expenses | $5.9M | $3.7M | $43.4M | $3.2M | — |
| Operating income | −$5.9M | −$3.7M | −$43.4M | −$3.2M | — |
| EBITDA | −$6.9M | $1.0M | −$51.1M | −$3.2M | — |
| Net income | −$6.9M | $1.0M | −$51.2M | −$3.2M | — |
| Basic EPSper basic share | — | $5.24 | -$586.50 | -$394.06 | -$544.78 |
| Diluted EPSper diluted share | — | $5.24 | -$586.50 | -$394.06 | -$544.78 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Parallel Advisors, LLC | 151.25K |
AdvisorShares Investments LLC | 122.18K |
MORGAN STANLEY | 37.8K |
JANE STREET GROUP, LLC | 30.43K |
XTX Topco Ltd | 15.09K |
CITADEL ADVISORS LLC | 11.69K |
Stonehage Fleming Financial Services Holdings Ltd | 89 |
UBS Group AG | 60 |
Caitlin John, LLC | 35 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data